Logo image of INAB

IN8BIO INC (INAB) Stock Fundamental Analysis

NASDAQ:INAB - Nasdaq - US45674E1091 - Common Stock - Currency: USD

0.169  0 (-1.74%)

After market: 0.1702 +0 (+0.71%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to INAB. INAB was compared to 566 industry peers in the Biotechnology industry. INAB may be in some trouble as it scores bad on both profitability and health. INAB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year INAB has reported negative net income.
INAB had a negative operating cash flow in the past year.
In the past 5 years INAB always reported negative net income.
INAB had a negative operating cash flow in each of the past 5 years.
INAB Yearly Net Income VS EBIT VS OCF VS FCFINAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -145.33%, INAB is doing worse than 84.45% of the companies in the same industry.
INAB has a Return On Equity of -210.23%. This is in the lower half of the industry: INAB underperforms 70.14% of its industry peers.
Industry RankSector Rank
ROA -145.33%
ROE -210.23%
ROIC N/A
ROA(3y)-106.89%
ROA(5y)-80.96%
ROE(3y)-152.01%
ROE(5y)-110.17%
ROIC(3y)N/A
ROIC(5y)N/A
INAB Yearly ROA, ROE, ROICINAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K 1.5K

1.3 Margins

INAB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INAB Yearly Profit, Operating, Gross MarginsINAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for INAB has been increased compared to 1 year ago.
The number of shares outstanding for INAB has been increased compared to 5 years ago.
The debt/assets ratio for INAB is higher compared to a year ago.
INAB Yearly Shares OutstandingINAB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
INAB Yearly Total Debt VS Total AssetsINAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -11.08, we must say that INAB is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of INAB (-11.08) is worse than 77.03% of its industry peers.
INAB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of INAB (0.02) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -11.08
ROIC/WACCN/A
WACCN/A
INAB Yearly LT Debt VS Equity VS FCFINAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 4.08 indicates that INAB has no problem at all paying its short term obligations.
INAB has a Current ratio of 4.08. This is comparable to the rest of the industry: INAB outperforms 48.06% of its industry peers.
INAB has a Quick Ratio of 4.08. This indicates that INAB is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.08, INAB perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.08
Quick Ratio 4.08
INAB Yearly Current Assets VS Current LiabilitesINAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

INAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.57%, which is quite impressive.
EPS 1Y (TTM)42.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, INAB will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.44% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y63.07%
EPS Next 2Y26.59%
EPS Next 3Y15.33%
EPS Next 5Y19.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INAB Yearly Revenue VS EstimatesINAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 50M 100M 150M
INAB Yearly EPS VS EstimatesINAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INAB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INAB Price Earnings VS Forward Price EarningsINAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INAB Per share dataINAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

INAB's earnings are expected to grow with 15.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.59%
EPS Next 3Y15.33%

More info and screens

0

5. Dividend

5.1 Amount

INAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IN8BIO INC

NASDAQ:INAB (4/30/2025, 7:51:58 PM)

After market: 0.1702 +0 (+0.71%)

0.169

0 (-1.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13 2025-03-13/amc
Earnings (Next)N/A N/A
Inst Owners46.89%
Inst Owner Change0%
Ins Owners5.71%
Ins Owner Change0%
Market Cap13.73M
Analysts82
Price Target2.66 (1473.96%)
Short Float %0.66%
Short Ratio0.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.9%
Min EPS beat(2)8.09%
Max EPS beat(2)47.71%
EPS beat(4)2
Avg EPS beat(4)8.61%
Min EPS beat(4)-10.88%
Max EPS beat(4)47.71%
EPS beat(8)5
Avg EPS beat(8)2.27%
EPS beat(12)6
Avg EPS beat(12)-3.04%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-27.23%
PT rev (3m)-45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.76%
EPS NY rev (1m)0%
EPS NY rev (3m)28.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.95
P/tB 0.95
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0
BVpS0.18
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -145.33%
ROE -210.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-106.89%
ROA(5y)-80.96%
ROE(3y)-152.01%
ROE(5y)-110.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.19%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.08
Quick Ratio 4.08
Altman-Z -11.08
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)217.04%
Cap/Depr(5y)140.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.95%
EPS Next Y63.07%
EPS Next 2Y26.59%
EPS Next 3Y15.33%
EPS Next 5Y19.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.28%
EBIT Next 3Y-17.46%
EBIT Next 5Y-5.55%
FCF growth 1Y-1.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.47%
OCF growth 3YN/A
OCF growth 5YN/A